# Bhasker R. Mehta, M.D. – FDA 483, Jun 2, 2026

Source: https://www.keypedia.com/records/483/bhasker-r-mehta-md/b10def34-da34-4387-8e5e-248257a27df3

> FDA 483 for Bhasker R. Mehta, M.D. on June 02, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Bhasker R. Mehta, M.D.
- Inspection Date: 2026-06-02
- Product Type: drugs
- Office Name: Dallas District Office
- Summary: An FDA inspection of Bhasker R. Mehta, M.D., a clinical investigator in Arlington, TX, revealed significant deviations from the investigational plan. The firm failed to ensure subjects met eligibility criteria prior to randomization and improperly administered investigational product, leading to both underdosing and overdosing of study participants. These findings indicate serious non-compliance with clinical trial protocols.

## Related Officers

- [Terri E. Gibson](https://www.keypedia.com/people/terri-e-gibson/f1a80f95-a5c4-4cae-9a4b-e23f367770bb)

Company: https://www.keypedia.com/companies/bhasker-r-mehta-md/6354199d-7618-4cfc-9858-078f994cd9f3

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9